Eculizumab use in kidney transplantation

Current Opinion in Organ Transplantation

Volumn 20, Issue 6, 2015, Pages 643-651

  Johnson, Christopher K ^a   Leca, Nicolae ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibody mediated rejection; Atypical hemolytic uremic syndrome; C3 glomerulopathy; Complement system; Delayed graft function; Eculizumab; Kidney transplantation

Indexed keywords

COMPLEMENT COMPONENT C5; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANEMIA; ANTIBODY MEDIATED REJECTION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL (TOPIC); DELAYED GRAFT FUNCTION; DESENSITIZATION; DIARRHEA; DRUG SAFETY; GLOMERULOPATHY; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LEUKOPENIA; NAUSEA; OUTCOME ASSESSMENT; RECURRENT DISEASE; REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; GRAFT REJECTION; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; DELAYED GRAFT FUNCTION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 84947127540     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000249     Document Type: Review

References (39)

1. Li K, Fazekasova H, Wang N, et al. Functional modulation of human mono-cytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 2012; 217:65-73.
2. Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol 2015; 10:1636-1650.
3. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10:1517-1523.
4. Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hyper-tens 2013; 22:704-712.
5. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13:663-675.
6. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87:1061-1073.
7. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12:3337-3354.
8. Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2015; April. Epub ahead of print.
9. Matar D, Naqvi F, Racusen LC, et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014; 98:1205-1212.
10. Cheshire CAP, Apr 2014. Soliris (eculizumab) full prescribing information.
11. Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 2007; 18:2447-2456.
12. Fakhouri F, Frémeaux-Bacchi V, Noël LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494-499.
13. Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome postkidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014; 1:52.
14. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8:643-657.
15. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease andC3 GN. J Am Soc Nephrol 2012; 23:1229-1237.
16. Gurkan S, Fyfe B, Weiss L, et al. Eculizumab and recurrent C3 glomerulone-phritis. Pediatr Nephrol 2013; 28:1975-1981.
17. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
18. Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 2015; 15:1293-1302.
19. Bentall A, Tyan DB, Sequeira F, et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014; 27:1235-1243.
20. Burbach M, Suberbielle C, Brochériou I, et al. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 2014; 98:1056-1059.
21. Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompa-tible kidney transplantation. Transplantation 2014; 98:857-863.
22. González-Roncero F, Suñer M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012; 44:2690-2694.
23. Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 2013; 45:1022-1025.
24. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231-235.
25. Lonze BE, Dagher NN, Simpkins CE, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 2010; 10:2154-2160.
26. Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011; 24:e61-e66.
27. Stewart ZA, Collins TE, Schlueter AJ, et al. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012; 44:3033-3036.
28. Noone D, Al-Matrafi J, Tinckam K, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012; 12:2546-2553.
29. Ghirardo G, Benetti E, Poli F, et al. Plasmapheresis-resistantacutehumoralrejection successfully treated with anti-C5 antibody. Pediatr Transplant 2014; 18:E1-E5.
30. Amigo MC, Garcia-Torres R, Robles M, et al. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992; 19:1181-1185.
31. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 2003; 48:3320-3327.
32. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459-465.
33. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011; 11:2523-2527.
34. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013; 13:2179-2185.
35. Peng Q, Li K, Smyth LA, et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol 2012; 23:1474-1485.
36. Zaza G, Tomei P, Granata S, et al. Monoclonal antibody therapy and renal transplantation: focus on adverse effects. Toxins (Basel) 2014; 6:869-891.
37. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged >10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. Morb Mortal Wkly Rep 2015; 64:608-612.
38. Struijk GH, Bouts AH, Rijkers GT, et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013; 13:819-820.
39. Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making 2014; 34:1016-1029.